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tially higher cost of ReSTOR® compared to a monofocal; this
did not hold true for ARRAY-SA40®. ReSTOR® improves
patients’ satisfaction and is a cost saving alternative versus spec-
tacles in patients requiring cataract surgery.
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OBJECTIVES: Assessment of the costs-of-illness of venous leg
ulcers treated in German wound centers. METHODS: A nation-
wide cross-sectional studywas performed in 31 specializedwound
centers, including ofﬁce- and clinic-based dermatologists, sur-
geons, GPs and internists. Patients with conﬁrmed diagnosis of
venous leg ulcer(s) were consecutively recruited, interviewed and
asked to ﬁll standardized questionnaires. Major outcomes param-
eters were the direct, indirect and intangible costs related to the leg
ulcers from the societal perspective. The patient case report forms
included questions on former treatment, health related quality
of life, patient-relevant treatment beneﬁt (PBI) and quality of
care. The physician questionnaire focused on clinical data,
co-morbidity, co-medication, wound status, resource consump-
tion and all relevant types of costs related to the treatment of
venous leg ulcers. RESULTS: In total, n = 218 patients (mean age:
69.8  12.0 years, median = 71) were enrolled, including 62.1%
women and 37.9% men. The median duration of ulceration was
7.0 years. The average total costs per patient summed up to €9569
per year, including €8658 of direct costs and €911 of indirect costs.
The major proportions of direct costs were statutory health
insurance costs (€7631) and out-of-pocket expenses (€1027). The
most cost-driving factor was inpatient treatment (€3568), fol-
lowed by non-drug treatment expenses (€740) and nursing fees in
home care (€212). Health-related quality of life was considerably
impaired in almost all of the patients, indicating high intangible
costs of illness. CONCLUSIONS: Venous leg ulcers in Germany
are associated with relevant direct, indirect and intangible costs
suggesting early and qualiﬁed disease management. are associated
with relevant direct, indirect and intangible costs suggesting early
and qualiﬁed disease management.
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OBJECTIVES: Severe chronic CHE is underreported in
Germany. Reported data refer to work-related disease only and
even these are incomplete (Diepgen & Schmidt 2002). However,
CHE has a huge impact on the working capacity of patients. We
therefore targeted to estimate the total costs of severe CHE in
Germany using epidemiological data in addition to reported
cases of occupational CHE. METHODS: In a ﬁrst step data on
151 patients with occupational CHE were analyzed to obtain
information on direct and indirect costs of CHE. In a second step
epidemiological information was used to create three groups of
patients: 1) DGUV-patients (German Statutory Accident Insur-
ance, payer for work-related diseases/accidents); 2) non-DGUV
but full-time working patients and 3) non-DGUV, non-full time
working patients. Cost assumptions per group were adjusted to
reﬂect differing reimbursement catalogues (DGUV vs. Statutory
Sick Funds), impact of work absenteeism and employment status.
Extensive scenario analyses with varying assumptions on costs
and epidemiology were conducted. RESULTS: Group 1 included
23,631 patients, group 299,735 and group 3,115,253. Per
patient costs per group amounted to €8799 in group 1, €5341 in
group 2 and €1035 in group 3. This results in total societal costs
of €860 million for severe, chronic CHE in Germany. Scenario
analyses showed a range of €348 million to €1.59 billion. 67% of
total costs were indirect costs, Statutory Sick Funds were the
payer for 15.5%, patients for 11.5% and DGUV for 6%. CON-
CLUSIONS: Total annual societal costs of severe chronic CHE
are enormous, despite the fact that CHE is not a life-threatening
disease. These costs are similar to the total costs of psoriasis,
colon or stomach cancer in Germany. The main cost component
are indirect costs. Effective therapeutic or preventive measures
would have a huge potential for cost savings.
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OBJECTIVES: Cataract is the principal cause of blindness
worldwide and surgery is the only effective treatment for this
condition. Several multifocal intraocular lenses (MFIOL) are cur-
rently available to reduce or eliminate the need for eyeglasses
after surgery. The objective of this survey was to collect data in
the Netherlands on the associated costs to society of wearing
spectacles after cataract surgery. This,information was requested
to support a health economics evaluation of MFIOLs.
METHODS: Cross-sectional survey of centers that recruited
patients who wore spectacles after cataract surgery and agreed to
complete a questionnaire. RESULTS: Forty-seven patients were
recruited with a mean age of 74.2 years and sex-ratio 2 females:
1 male. On average, they underwent cataract surgery 2.1 years
prior to recruitment. A total of 97.9% had a private insurance
which covered spectacle cost, at least partially, in 69.0% of the
cases. Spectacles were prescribed by an optometrist for 48.9%,
and glasses were multi focal in 76.7% of the cases (varifocal
44.7%). Spectacles were changed within 3 years in 50.0% of the
patients. Patients live an average of 11.5 km from their ophthal-
mologist and 5.8 k from their opticians. Mean spectacle cost
was €586.5, 43.7% being paid by private insurance. More than
80% of the patients wear glasses for watching TV, near reading,
going to movies or theater, driving, walking outside and visiting
friends. Dissatisfaction with glasses was rather rare at 13.7% of
the patients; 47.6% of the subjects expressed some willingness
to pay (at least €0.5 per day) to avoid wearing spectacles. CON-
CLUSIONS: Although almost half of all subjects had a private
health insurance, a large part of the cost was borne by patients.
The total economic burden of spectacles was not limited to the
spectacles; repeated travel related to eye care should also be
considered. There is some willingness to pay to be free of spec-
tacles in this population.
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OBJECTIVES: Otitis media (OM) is one of the most common
childhood diseases. By age 3-years, 50–85% of children have had
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acute OM. Although, considered a minor condition, OM often
disrupts the daily routine, forcing parents to stay at home. This
study was designed to investigate the productivity loss and soci-
etal burden of OM in several European countries. METHODS:
An internet-survey was conducted in 7 EU-countries: France(F),
Great Britain(GB), Germany(D), Spain(E), Italy(I), The Nether-
lands(NL), Belgium(B). Questions regarding the most recent
childhood-illness-episode included: symptoms, medical diagnosis
if medical help was sought, time taken off work, leisure time loss
and diminished productivity at work. Data were analyzed for
OM-episodes. RESULTS: 14916 parents of children (<5-years)
reported a child-illness-episode in the previous year, completing
an e-mailed 17-question-survey. A total of 1479 OM-episodes
were reported (65%–75% occurring in the previous month).
The proportion of parents seeking medical help ranged from
47%(NL) to 88.7%(E). In E, 27.9% of parents went to the
Emergency Room, 10–15% (D,I,GB); 2–4% (NL,B,F). Hospitali-
sation was required for 3.6–7.7% for an average 1.4–6.8 days.
12.8% (F,B)–21.7% (NL) parents took a median of 10–16 hours
off work. A further 23.4% (NL) to 82.4% (UK) parents reported
being less productive at work. In addition, 47.5% (D) to 68.1%
(B) said they had to take time out of their leisure time to visit the
doctor or the pharmacist. Children had an average of 2.2–2.7
episodes in the previous year; 28–57% had had 3 episodes in
the previous year. Indirect costs amounted to a total of €115.36
(NL) to €300.41 (UK) per episode. CONCLUSIONS: Indirect
costs due to lost productivity, either due to time taken off work,
reduced productivity at work or leisure time loss represents a
signiﬁcant proportion of the costs associated with OM. An inter-
vention that would reduce the incidence, prevalence or duration
of OM would have a major impact on the societal burden.
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OBJECTIVES: Several studies have shown that reducing the
intraocular pressure (IOP) of patients with glaucoma to a target
level 18 mmHg prevents further visual ﬁeld deterioration. The
objective of this analysis was to compare the IOP-lowering
efﬁcacy and the cost-effectiveness of ﬁxed combinations of
brimonidine/timolol and dorzolamide/timolol in 10 European
countries. METHODS: Efﬁcacy and safety of the two ﬁxed com-
bination products were based on pooled data from two head-to-
head trials. Efﬁcacy was measured as the percentage of patients
reaching an IOP level 18 mmHg or 13 mmHg after 3 months
of treatment. Discontinuation rates due to adverse events were
also included in the model, and it was assumed that patients
discontinuing treatment had an extra ophthalmologist visit. All
drug costs were market prices inclusive of VAT, and ophthal-
mologist visit costs were priced using ofﬁcial tariffs. RESULTS:
Clinical efﬁcacy data showed that brimonidine/timolol was more
effective than dorzolamide/timolol in terms of lowering patients’
IOP. The percentage of patients reaching IOP 13 mmHg was
32.65% for brimonidine/timolol and 13.95% for dorzolamide/
timolol (p = 0.0359). 77.55% of brimonidine/timolol patients
reached a target IOP  18 mmHg, and 60.47% of dorzolamide/
timolol patients did (p = 0.0756). Three months’ health care
costs for patients treated with brimonidine/timolol were compa-
rable to those of dorzolamide/timolol treatment in the 10 studied
countries. Brimonidine/timolol was less costly and more effective
in Italy, Spain, and Norway, whereas it was more effective and
slightly more costly in Germany, the UK, Denmark, Sweden, the
The Netherlands, Portugal and France. In these countries, the
incremental cost per patient reaching a target IOP  18 mmHg
ranged from £0.32 (UK) to €26.66 (The Netherlands). For IOP
 13 mm Hg the range was £0.29 (UK) to €24.36 (The Nether-
lands). CONCLUSIONS: Brimonidine/timolol is effective in
terms of lowering IOP and is a cost-effective treatment strategy
for patients with glaucoma.
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OBJECTIVES: To determine current treatment strategies and
evaluate one year consumption of health care resources for
patients with uveitis in France. METHODS: Data abstracted
from charts of consecutive patients (N = 100) from 4 French
referral centers with 12 months follow-up after the ﬁrst visit
included basic demographic data, clinical parameters, and all
disease- or treatment-related resource consumption. Direct
health care costs were estimated using publicly available stan-
dard unit costs. Indirect costs were based on standard sick leave
for each type of inpatient admission or outpatient intervention
and a gender-speciﬁc cost of employment. RESULTS: Most
patients (82%) were below age 60 (retirement age). Patients
had posterior uveitis (36%), panuveitis (33%), chronic anterior
(24%) and intermediate uveitis (7%). Patients received drug
treatments (91%), triamcinolone or dexamethasone injections
(8%), and laser treatment (2%). Mean direct costs per patient
were €3403 ($5045). Inpatient stays accounted for the largest
proportion, with a mean cost of €2889 ($4283) per year. For
patients below 60 years with an admission or intervention, the
estimated average productivity loss was €1750 ($2594), leading
to a mean indirect cost of €830 ($1230) per patient. The esti-
mated total minimum annual costs per patient were €4230
($6271). CONCLUSIONS: Annual treatment costs in this
sample were driven by frequent, extended inpatient stays. This
may be due to the more severely diseased patients who are
treated in these specialized centers. In the current sample, most
patients were of working age, suggesting a substantial amount of
indirect costs arising from sick leave.
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OBJECTIVES: Models have previously focused on short-term
costs and effectiveness measured in terms of intraocular (IOP)
control. This model will assess the long-term effects of continued
medical treatment in terms of glaucoma progression, low vision
and quality-of-life. METHODS: A cost-utility analysis using a
ten-year Markov model of ﬁrst-line latanoprost, bimatoprost,
travoprost or timolol, followed by second / third-line. Transition
probabilities for this model were from a systematic review and
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